Asunercept, CAS 1450882-18-4

Product Description: Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD)[1][2][3].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]Merz C, et al. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro. Anticancer Drugs. 2015 Aug;26(7):716-27. /[2]Krendyukov A, et al. Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies. Cancer Manag Res. 2019 Sep 2;11:8095-8100. /[3]Radujkovic A, et al. Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile. Cancers (Basel). 2020 Dec 8;12(12):3683.

CAS Number: 1450882-18-4

Molecular Weight: N/A

Compound Purity: 98.13

Research Area: Cancer; Inflammation/Immunology

Solubility: 10 mM in DMSO

Target: TNF Receptor

• Artikelnummer: MEXHY-P99445-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99445-10
• Green Labware: Nein
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK